Introduction {#Sec1}
============

Glaucoma is a leading cause of blindness in Latin America and worldwide \[[@CR1]\]. Globally, nearly 80 million people are projected to be diagnosed with glaucoma in 2020, more than 8 million of whom are expected to be from Latin America \[[@CR1]\]. Elevated intraocular pressure (IOP) is a major risk factor for primary open-angle glaucoma \[[@CR2]\]; the primary treatment approach to slow progression of glaucoma and ocular hypertension is reducing IOP \[[@CR3]\]. Several topical IOP-lowering medications exist; these include medications that decrease aqueous humor production and increase aqueous humor outflow (e.g., carbonic anhydrase inhibitors, β-blockers, α-agonists) \[[@CR3]\]. Treatment with a single topical agent is often insufficient to control IOP, and many patients require an additional IOP-lowering agent to achieve their targets \[[@CR3], [@CR4]\]. Concomitant use of multiple ocular hypotensive agents may be inconvenient and has been associated with increased risk of drug washout \[[@CR5]\], decreased adherence and persistence \[[@CR6], [@CR7]\], increased exposure to preservatives and risk of preservative-related ocular surface disease \[[@CR8], [@CR9]\], and potentially higher treatment costs \[[@CR10]\].

Fixed-combination medications for glaucoma enable treatment with multiple mechanisms of action in a single topical medication, providing additive IOP-lowering efficacy without increasing treatment complexity or introducing risk of drug washout. The fixed-combination therapy brinzolamide 1%/timolol 0.5% (BRINZ/TIM-FC; Azarga^®^; Alcon Laboratories, Inc., Fort Worth, TX, USA) combines a carbonic anhydrase inhibitor (CAI) with a β-blocker and has IOP-lowering efficacy greater than the component monotherapies \[[@CR11]\]. Although the safety and efficacy of BRINZ/TIM-FC have been demonstrated in previous studies \[[@CR12], [@CR13]\], there are few data on the IOP-lowering efficacy of BRINZ/TIM-FC in patients who transitioned to BRINZ/TIM-FC because of insufficient IOP control or intolerance of a fixed combination containing the α-agonist brimonidine. Brimonidine 0.2%/timolol 0.5% fixed-combination therapy (BRIM/TIM-FC; Combigan^®^; Allergan, Inc., Irvine, CA, USA) has shown efficacy greater than brimonidine or timolol monotherapy alone in patients with glaucoma or ocular hypertension \[[@CR14]\].

The objective of this study was to assess the efficacy and tolerability of transitioning to BRINZ/TIM-FC from prior BRIM/TIM-FC in Latin American patients with open-angle glaucoma or ocular hypertension.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was an 8-week, multicenter, open-label study conducted at six clinical sites in Argentina, Chile, and Mexico from December 2011 to February 2013 that was designed to evaluate the tolerability and efficacy of changing to BRINZ/TIM-FC from prior BRIM/TIM-FC in patients with open-angle glaucoma or ocular hypertension. The study consisted of one screening/baseline visit and two follow-up visits conducted after 4 and 8 weeks of treatment. At screening/baseline, patient diagnosis was recorded on a case report form. The form contained a single diagnosis entry for both eyes; in the event that qualifying glaucoma diagnoses differed between eyes, a diagnosis of "non-specified glaucoma" was recorded. Patients received BRINZ/TIM-FC and were instructed to self-administer one drop to each eye twice daily (at 8 a.m. and 8 p.m.) throughout the study. Patients were required to discontinue any prior ocular hypotensive therapy at screening. To represent typical clinical practice patterns and to avoid potentially unsafe increases in IOP, there was no washout period between discontinuation of prior medication and initiation of BRINZ/TIM-FC therapy. The following assessments were performed at baseline: best-corrected monocular visual acuity (BCVA) assessment; biomicroscopy of eyelids, conjunctiva, cornea, iris, anterior chamber, and lens; confirmation of open-angle glaucoma by gonioscopy; IOP measurement by Goldmann applanation tonometry; and survey-based assessment of ocular symptoms. BCVA, biomicroscopy, and IOP were also assessed at weeks 4 and 8. At week 8, patients completed the ocular symptom survey, global preference response, and adherence questionnaire; investigators completed the global preference response for each patient based on the patient's IOP response to BRINZ/TIM-FC.

The study protocol was approved by all relevant institutional review boards or independent ethics committees, and the study was performed in compliance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice. Before entering the study, all patients provided written informed consent. This trial is registered at Clinicaltrials.gov, number NCT01518244.

Patients {#Sec4}
--------

Eligible patients were aged ≥18 years with an existing diagnosis of ocular hypertension or primary, exfoliative, or pigment-dispersion open-angle glaucoma in ≥1 eye and were on a stable BRIM/TIM-FC treatment regimen for ≥30 days before screening. Other inclusion criteria were IOP between 19 and 35 mmHg in ≥1 eye while on BRIM/TIM-FC, BCVA of 20/200 (Snellen) or better in each eye, and willingness to discontinue use of all other ocular hypotensive agents at screening and throughout the study. Patients must have had IOP considered safe by the investigators in both eyes to ensure clinical stability of vision and the optic nerve. Key exclusion criteria were hypersensitivity to the study medication; presence of a primary or secondary glaucoma other than exfoliative or pigment-dispersion glaucoma; ocular herpes simplex; any abnormality preventing reliable applanation tonometry or examination of the ocular fundus or anterior chamber; corneal dystrophy; conjunctivitis, keratitis, or uveitis; intraocular surgery ≤3 months before screening; cardiopulmonary conditions that precluded safe administration of a topical β-blocker; use of systemic medications that affect IOP without a stable course for ≥7 days before screening and throughout the study; use of corticosteroids ≤30 days before screening; and risk of visual field or visual acuity worsening as a consequence of participation in the study.

Efficacy Outcomes {#Sec5}
-----------------

The primary efficacy variable was change in IOP from baseline to week 8. The percentage of patients with IOP ≤18 mmHg at week 8 was the secondary efficacy variable. IOP was assessed by the same operator with the same tonometer at least 2 h after the morning instillation of the study drug and at approximately the same time of day for all visits. Exploratory efficacy variables were ocular symptom survey responses by visit and change from baseline to week 8, adherence questionnaire responses at week 8, and patient and investigator global preference responses at week 8. The global preference questionnaire consisted of a single question with a forced-choice binary response (i.e., preferred study medication \[BRINZ/TIM-FC\] or preferred prior medication \[BRIM/TIM-FC\]).

Safety Outcomes {#Sec6}
---------------

Safety was assessed by monitoring adverse event (AE) reports. Ocular signs (evaluated by slit-lamp biomicroscopy) and BCVA were evaluated for each eye at all study visits.

Statistical Analysis {#Sec7}
--------------------

If only one eye was eligible for inclusion and treatment, this eye was selected for the efficacy analysis; if both eyes were eligible, the worse eye (i.e., the eye with the higher IOP at baseline) was selected. If both eyes had equal IOP at baseline, the right eye was selected. Efficacy outcomes were analyzed in the intent-to-treat (ITT) population (i.e., patients who received BRINZ/TIM-FC and had ≥1 on-therapy study visit) and the per-protocol population (i.e., all subjects who received BRINZ/TIM-FC, completed all study visits, and satisfied all inclusion/exclusion criteria); missing data were not imputed. For the primary efficacy variable, differences in IOP measurements between baseline and week 8 were compared using Wilcoxon signed-rank tests. To assess the effect of time on IOP, changes in IOP across visits were evaluated using a repeated-measures analysis of variance. Ordinal responses from the ocular symptom survey were converted to a numeric scale (0 = none to 4 = severe); differences from baseline to week 8 were assessed using Wilcoxon signed-rank tests and sign tests. Patient and investigator responses to the global preference questionnaire were assessed with exact binomial tests. Safety analyses were performed in the safety population (i.e., all patients who received ≥1 dose of BRINZ/TIM-FC). Descriptive statistics were provided for demographic, adherence, and safety endpoints. Statistical analyses were performed using SAS^®^, version 9.2 (SAS Institute Inc., Cary, NC, USA); all statistical tests were two-tailed with a significance level of 0.05.

Results {#Sec8}
=======

Patients {#Sec9}
--------

Fifty patients were screened and enrolled in the study and included in the safety population. Open anterior chamber angle was confirmed for all patients. Mean ± SD patient age was 66.7 ± 11.5 years (range 29--87 years); 61.2% of patients were female, and 89.8% were Hispanic (Table [1](#Tab1){ref-type="table"}). Three patients discontinued because of AEs (keratitis, bacterial conjunctivitis, and eye irritation); one patient discontinued between baseline and week 4 and was excluded from the ITT analysis (*n* = 49), and two patients discontinued between weeks 4 and 8.Table 1Patient demographics (intent-to-treat population)CharacteristicBRINZ/TIM-FC (*n* = 49)Age, years Mean ± SD66.7 ± 11.5 Range29--87Sex, *n* (%) Female30 (61.2) Male19 (38.8)Race, *n* (%) Hispanic44 (89.8) Caucasian5 (10.2)Weight, mean ± SD, kg71.7 ± 15.3Height, mean ± SD, cm163.9 ± 11.1BMI, mean ± SD, kg/m^2^26.6 ± 4.7Diagnosis, *n* (%)^a^ Open-angle glaucoma26 (53.1) Non-specified glaucoma^b^22 (44.9) Ocular hypertension4 (8.2)*BMI* Body mass index, *BRINZ/TIM*-*FC* fixed-combination brinzolamide 1%/timolol 0.5%^a^Two diagnoses were recorded for some patients, causing the total number of diagnoses to exceed 49^b^Recorded for each patient who had a single glaucoma entry for both eyes; type of glaucoma was not allowed to be specified for each eye. Two patients presented with pseudoexfoliation glaucoma and were included as non-specified glaucoma; one patient had open-angle glaucoma in both eyes but was assigned to the non-specified glaucoma group because of a coding error

Efficacy {#Sec10}
--------

Efficacy data were similar in the ITT and per-protocol populations; results for the ITT population are presented. At baseline (on BRIM/TIM-FC; *n* = 49), mean ± SD IOP was 21.2 ± 2.5 mmHg. Mean ± SD absolute IOP reduction from baseline to week 8 (on BRINZ/TIM-FC; *n* = 47) was −3.6 ± 3.0 mmHg (*P* \< 0.0001); mean ± SD percent IOP change from baseline to week 8 was −17.1 ± 13.7%. Mean IOP decreased from baseline to week 4 (*n* = 49) and was maintained through week 8 (Fig. [1](#Fig1){ref-type="fig"}). At week 8, 55.3% of patients (*n* = 26/47) achieved the target IOP of ≤18 mmHg.Fig. 1Mean ± SD IOP throughout the study (intent-to-treat population). Percent IOP reduction from baseline to week 4 and week 8 is indicated inside *bars*; *gray bars* indicate IOP with BRINZ/TIM-FC treatment. \**P* \< 0.0001, week 8 versus baseline; Wilcoxon test. Overall effect of time on IOP, *P* \< 0.0001; repeated-measures analysis of variance. *BRINZ/TIM*-*FC* fixed-combination brinzolamide 1%/timolol 0.5%, *IOP* intraocular pressure

The proportion of patients reporting the symptoms described in the ocular symptom survey decreased from baseline to week 8, except for crusting around the eyes, which increased from 12.2% (*n* = 6/49) to 27.7% (*n* = 13/47; Table [2](#Tab2){ref-type="table"}). Dry eyes; excessive tearing; and itching of the eyes, eyelids, or the area around the eyes were significantly improved from baseline to week 8 (all *P* \< 0.05; Table [2](#Tab2){ref-type="table"}).Table 2Ocular symptom survey by visit and change from baseline (intent-to-treat population)QuestionPatients, *n* (%)Change from baseline to week 8^b^ (*n* = 47)Baseline^a^ (**n = 49**)Week 8^a^ (**n =  47**)Mean ± SD*P* valueHave you had dry eyes since your last visit?17 (35.4)^c^9 (19.1)−0.35 ± 1.16\<0.0486^d^Have you had pain in or around your eyes when in the light since your last visit?16 (32.7)11 (23.4)−0.30 ± 1.25\<0.1321^d^Have you teared more than normal since your last visit?16 (32.7)4 (8.5)−0.34 ± 0.940.0097^d^Did your eye drops sting or burn when you instilled them?26 (53.1)18 (38.3)−0.53 ± 1.540.2295^e^Have you had crusting around your eyes since your last visit?6 (12.2)13 (27.7)0.30 ± 1.280.1455^d^Have you had itching of eyes, eyelids, or the area around your eyes since your last visit?19 (38.8)8 (17.0)−0.55 ± 0.950.0007^e^Have you had a feeling of irritation in your eyes since your last visit?18 (36.7)8 (17.0)−0.37 ± 1.180.0509^d^Have you noticed redness in your treated eyes?11 (22.4)10 (21.3)−0.23 ± 1.340.2370^d^Have other people commented about redness in your treated eyes?15 (30.6)8 (17.0)NANAHow easy is it for you to instill your eye drops in your eyes? Very difficult2 (4.1)0 (0.0)NANA Difficult2 (4.1)4 (8.5)NANA Easy19 (38.8)18 (38.3)NANA Very easy26 (53.1)25 (53.2)NANA*NA* Not applicable^a^Values represent "yes" responses to each question, with the exception of the question "How easy is it for you to instill your eye drops in your eyes?" for which responses regarding levels of ease with instillation are shown^b^Values represent change from baseline to week 8 in answers on a 5-point scale of symptom severity (0 = none; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe). Negative values indicate an improvement in ocular symptoms^c^ *n* = 48^d^Wilcoxon test^e^Sign test

Most patients (89.4%, *n* = 42/47) preferred BRINZ/TIM-FC to BRIM/TIM-FC (*P* \< 0.0001). Investigators preferred BRINZ/TIM-FC to BRIM/TIM-FC for nearly all patients (95.7%, *n* = 45/47; *P* \< 0.0001).

All but 1 patient (97.9%, *n* = 46/47) were very confident that they would adhere to their preferred glaucoma medication if it was prescribed by their doctor, compared with 61.7% (*n* = 29/47) who were very confident that they would adhere to their non-preferred medication if it was prescribed (Table [3](#Tab3){ref-type="table"}). In total, 87.2% (*n* = 41/47) of patients were very confident they would use a prescribed medication if it did not make their eyes burn or sting, whereas 59.6% (*n* = 28/47) of patients were very confident that they would use a prescribed medication if it did cause such symptoms (Table [3](#Tab3){ref-type="table"}).Table 3Adherence questionnaire (intent-to-treat population)Question, *n* (%)Week 8 (*n* = 47)How confident is the patient that he/she will use glaucoma medication as prescribed if the doctor: Prescribed the medication preferred in the study  Not at all confident0  Somewhat confident1 (2.1)  Very confident46 (97.9) Prescribed the medication not preferred in the study  Not at all confident12 (25.5)  Somewhat confident6 (12.8)  Very confident29 (61.7) Prescribed a medication that makes the eyes burn or sting  Not at all confident11 (23.4)  Somewhat confident8 (17.0)  Very confident28 (59.6) Prescribed a medication that does not make the eyes burn or sting  Not at all confident4 (8.5)  Somewhat confident2 (4.3)  Very confident41 (87.2)

Safety {#Sec11}
------

A total of 13 AEs were reported for 10 patients (Table [4](#Tab4){ref-type="table"}). Most AEs were mild or moderate in intensity, and all resolved with or without treatment. Eight AEs in five patients were considered related to BRINZ/TIM-FC; the most common treatment-related AEs were eye irritation (*n* = 4) and abnormal sensation in the eye (*n* = 2). There were no serious AEs.Table 4Summary of adverse events (safety population)Adverse events, *n* (%)BRINZ/TIM-FC (*n* = 50)Patients with ≥1 AE10 (20.0)Treatment-emergent AEs: Eye irritation4 (8.0) Abnormal sensation in eye2 (4.0) Conjunctivitis2 (4.0) Foreign body sensation in eyes1 (2.0) Keratitis1 (2.0) Bacterial conjunctivitis1 (2.0) Viral conjunctivitis1 (2.0) Gastroenteritis1 (2.0)Patients with ≥1 treatment-related AE5 (10.0)Treatment-related AEs: Eye irritation4 (8.0) Abnormal sensation2 (4.0) Foreign body sensation1 (2.0) Keratitis1 (2.0)*AE* Adverse event, *BRINZ/TIM*-*FC* fixed-combination brinzolamide 1%/timolol 0.5%

Approximately 50% of patients showed lens abnormalities in the slit-lamp examination in both eyes at baseline and follow-up visits; the most common lens abnormality was mild nuclear opacity. Findings for cornea, iris/anterior chamber, eyelids, and conjunctiva were generally unchanged from baseline at weeks 4 and 8. No marked differences in BCVA from baseline to week 4 or week 8 were observed.

Discussion {#Sec12}
==========

Fixed-combination therapies for glaucoma provide an effective and convenient therapeutic option for patients who cannot maintain target IOP reduction on monotherapy alone. BRINZ/TIM-FC and BRIM/TIM-FC each provide two ocular hypotensive agents in a single eye drop and achieve greater IOP reductions than their individual components alone. Compared with concomitant therapy with their unfixed components, fixed-combination therapies provide similar IOP-lowering efficacy, decreased treatment complexity, lower risk of drug washout, decreased preservative exposure and preservative-related ocular discomfort, and may reduce treatment costs \[[@CR5], [@CR8]--[@CR10]\]. By simplifying treatment regimens and decreasing risk of preservative-related ocular side effects, fixed combinations may also promote improved treatment adherence.

In the current study of Latin American patients with open-angle glaucoma or ocular hypertension, a significant reduction in IOP was observed after patients were transitioned from twice-daily BRIM/TIM-FC to twice-daily BRINZ/TIM-FC; mean IOP decreased from baseline to week 8 by 3.6 mmHg. All enrolled patients had a minimum IOP ≥19 mmHg with BRIM/TIM-FC, and more than half of patients (*n* = 26/47) achieved the target IOP of ≤18 mmHg after 8 weeks of treatment with BRINZ/TIM-FC. Results of the ocular symptom survey showed that patients reported greater ocular comfort with BRINZ/TIM-FC compared with BRIM/TIM-FC. Nearly 90% of patients preferred BRINZ/TIM-FC to BRIM/TIM-FC, possibly because of the improved tolerability and comfort reported for BRINZ/TIM-FC; investigators preferred BRINZ/TIM-FC for nearly all patients (95.7%). No substantial changes in ocular signs or BCVA were observed throughout the study, and the safety profile of BRINZ/TIM-FC was similar to previous reports \[[@CR12], [@CR13]\]. All AEs were consistent with AEs previously reported with topical β-blockers and CAIs.

The observed reduction in IOP with BRINZ/TIM-FC was evident after 4 weeks of treatment and was maintained through 8 weeks. Mean IOP with BRINZ/TIM-FC treatment was 17.35 mmHg and 17.51 mmHg at weeks 4 and 8, respectively; at week 8, mean IOP was reduced by 17.1% from baseline levels (21.2 mmHg), when patients were receiving BRIM/TIM-FC. Furthermore, whereas no patients had IOP \<19 mmHg at baseline, 55.3% of patients achieved the target IOP of ≤18 mmHg after 8 weeks of BRINZ/TIM-FC treatment. Maintaining IOP ≤18 mmHg has been associated with less disease progression and increased stability of visual fields over several years of patient follow-up. A meta-analysis of five studies of patients with open-angle glaucoma found that elevated IOP was a significant risk factor for disease progression over 5 years; visual fields were stable in 82% of patients with mean IOP of 13--17 mmHg compared with only 49% of patients with mean IOP \>18 mmHg \[[@CR15]\]. Mean IOP was 20.0 mmHg in patients with signs of disease progression compared with 17.1 mmHg in patients without progression \[[@CR15]\]. Likewise, the Advanced Glaucoma Intervention Study comparison of surgical interventions for glaucoma demonstrated that visual field progression was decreased in patients who consistently maintained IOP levels ≤18 mmHg over 6 years compared with patients who had higher IOP levels \[[@CR16]\]. In the Canadian Glaucoma Study, among 249 patients with open-angle glaucoma, those with mean IOP \>17 mmHg had significantly higher cumulative progression compared with those with mean IOP \<15 mmHg \[[@CR17]\]; this study also found that the risk of progression increased by 19% for every 1-mmHg increase in mean IOP \[[@CR17]\]. Similarly, the Early Manifest Glaucoma Trial demonstrated that the risk of progression decreased by \~10% for every 1-mmHg decrease in IOP from baseline at follow-up visits \[[@CR18]\]. This finding was further supported by the Canadian Glaucoma Study follow-up report, which showed that even a modest IOP reduction in patients with glaucoma progression significantly slowed the rate of visual field decline \[[@CR19]\]. In the current study, BRINZ/TIM-FC therapy led to significant IOP reductions from levels maintained with BRIM/TIM-FC. This finding is consistent with the results of a systematic review and meta-analysis that demonstrated greater mean diurnal IOP reduction with BRINZ/TIM-FC compared with BRIM/TIM-FC (−8.3 mmHg versus −6.6 mmHg, respectively; overall difference, 1.7 mmHg) \[[@CR20]\]. The difference in IOP with BRINZ/TIM-FC versus BRIM/TIM-FC in the current study was of greater magnitude than was previously reported \[[@CR20]\]; however, the current study did not control for potential non-compliance with prior BRIM/TIM-FC.

The safety and tolerability profiles of BRINZ/TIM-FC and BRIM/TIM-FC in the current study were similar to previous reports. In a large, multicenter, observational study of more than 14,000 patients throughout Germany who transitioned to BRINZ/TIM-FC from prior IOP-lowering medications, nearly 90% of patients judged the tolerability of BRINZ/TIM-FC positively \[[@CR13]\]. A total of 75.9% of evaluable patients reported a preference for BRINZ/TIM-FC compared with 8.6% who reported a preference for their previous therapy \[[@CR13]\]. Of more than 200 patients who were transitioned from BRIM/TIM-FC to BRINZ/TIM-FC, more patients rated BRINZ/TIM-FC tolerability favorably (86.5%) compared with BRIM/TIM-FC tolerability (32.1%); similar to the results of the current study, more patients reported a preference for BRINZ/TIM-FC (75.8%) compared with BRIM/TIM-FC (6.6%) \[[@CR13]\].

The open-label, single-arm design, lack of active control, 8-week follow-up, and subjective nature of the surveys are potential limitations of this study. IOP was assessed and recorded by the same operator for each patient throughout the study, which could have introduced bias based on the unmasked nature of the study. The single baseline IOP assessment for determination of patient eligibility did not allow adjustment for potential noncompliance with BRIM/TIM-FC at screening, and regression to the mean may have affected study results. Inclusion of patients with IOP considered safe for study participation may have introduced patient selection bias. Adherence with BRINZ/TIM-FC may have been higher because of the effect of participation in a clinical trial. Furthermore, the preference questionnaire consisted of a binary choice question; therefore, patients who may have had no medication preference were prompted to choose between BRIM/TIM-FC and BRINZ/TIM-FC. Prior intolerance to BRIM/TIM-FC may have introduced bias to patients' questionnaire responses. Future studies including a crossover design and longer follow-up durations would provide valuable data regarding long-term treatment adherence, tolerability, efficacy, and medication preference in this patient population.

Conclusion {#Sec13}
==========

In this study of patients transitioning from BRIM/TIM-FC to BRINZ/TIM-FC because of insufficient IOP reduction or intolerance, BRINZ/TIM-FC significantly reduced IOP after 4 weeks of treatment and maintained IOP reductions through 8 weeks; more than half of the patients studied achieved target IOP (i.e., ≤18 mmHg) after 8 weeks of treatment. BRINZ/TIM-FC was preferred by significantly more patients and investigators and was associated with improved tolerability compared with BRIM/TIM-FC. These results suggest that BRINZ/TIM-FC is an effective and well-tolerated option for patients transitioning from BRIM/TIM-FC.
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